Dossier assessment
Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)
Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: indication of considerable added benefit. PPMS: indication of lesser benefit than appropriate comparator therapy
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-06
- Commission
- Commission awarded on 16.01.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06
Status: Commission completed